Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.070
+0.060 (1.99%)
Aug 14, 2026, 3:27 PM EDT - Market open
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending June 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
17.56
Revenue / Employee
$197,107
Employees
56
Market Cap
194.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Voyager Therapeutics | 34.46M |
| Alpha Cognition | 10.83M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Oramed Pharmaceuticals | 2.00M |
PYXS News
- 1 day ago - Pyxis Oncology Slides: Corporate presentation - Filings
- 1 day ago - Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - GlobeNewsWire
- 1 day ago - Pyxis Oncology Quarterly report: Q2 2026 - Filings
- 1 day ago - Pyxis Oncology Earnings release: Q2 2026 - Filings
- 11 days ago - Pyxis Oncology initiated with an Overweight at Wells Fargo - TheFly
- 6 weeks ago - Pyxis Oncology announces up to $114M private placement - TheFly
- 6 weeks ago - Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones - GlobeNewsWire
- 2 months ago - Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts